Mark. G. Currie
#163,671
Most Influential Person Now
Mark. G. Currie's AcademicInfluence.com Rankings
Mark. G. Curriebiology Degrees
Biology
#13122
World Rank
#16649
Historical Rank
Molecular Biology
#2178
World Rank
#2212
Historical Rank
Biochemistry
#2269
World Rank
#2416
Historical Rank
Download Badge
Chemistry Biology
Why Is Mark. G. Currie Influential?
(Suggest an Edit or Addition)Mark. G. Currie's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nitric oxide activates cyclooxygenase enzymes. (1993) (1423)
- A fluorometric assay for the measurement of nitrite in biological samples. (1993) (1043)
- Bioactive cardiac substances: potent vasorelaxant activity in mammalian atria. (1983) (698)
- Nitric oxide: a key mediator in the early and late phase of carrageenan‐induced rat paw inflammation (1996) (695)
- Guanylin: an endogenous activator of intestinal guanylate cyclase. (1992) (541)
- Purification and sequence analysis of bioactive atrial peptides (atriopeptins). (1984) (499)
- A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. (1999) (481)
- L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. (1994) (433)
- Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. (1993) (431)
- Atriopeptins as cardiac hormones. (1985) (379)
- Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety (2012) (375)
- Atriopeptin-immunoreactive neurons in the brain: presence in cardiovascular regulatory areas. (1985) (353)
- Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. (1998) (344)
- A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation (2012) (337)
- Prevention of Diabetic Vascular Dysfunction by Guanidines: Inhibition of Nitric Oxide Synthase Versus Advanced Glycation End-Product Formation (1993) (329)
- Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. (1994) (318)
- Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. (2002) (304)
- Two randomized trials of linaclotide for chronic constipation. (2011) (302)
- Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. (1995) (301)
- Evidence of peroxynitrite involvement in the carrageenan-induced rat paw edema. (1996) (273)
- Regulation of prostaglandin production by nitric oxide; an in vivo analysis (1995) (268)
- Peroxynitrite decomposition catalysts: therapeutics for peroxynitrite-mediated pathology. (1998) (260)
- Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. (2000) (246)
- Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. (2007) (245)
- Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. (1994) (242)
- Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors. (1995) (235)
- Characterization of the Cytoprotective Action of Peroxynitrite Decomposition Catalysts* (1998) (229)
- Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate. (2013) (223)
- A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics (2003) (220)
- Efficacy of linaclotide for patients with chronic constipation. (2010) (208)
- Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. (2000) (205)
- Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. (2010) (186)
- Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. (2010) (181)
- Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. (1996) (178)
- Guanylate cyclase C‐mediated antinociceptive effects of linaclotide in rodent models of visceral pain (2010) (171)
- Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. (1999) (162)
- Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. (2010) (158)
- Ventricular atriopeptin. Unmasking of messenger RNA and peptide synthesis by hypertrophy or dexamethasone. (1987) (153)
- Atriopeptins: a family of potent biologically active peptides derived from mammalian atria. (1984) (150)
- An atrial peptide is a potent renal vasodilator substance. (1984) (130)
- Randomised clinical trials: linaclotide phase 3 studies in IBS‐C – a prespecified further analysis based on European Medicines Agency‐specified endpoints (2013) (127)
- Protective effects of a superoxide dismutase mimetic and peroxynitrite decomposition catalysts in endotoxin‐induced intestinal damage (1999) (127)
- Pilot Study on the Effect of Linaclotide in Patients With Chronic Constipation (2009) (120)
- Pharmacologic Properties, Metabolism, and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation (2013) (119)
- Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity. (1997) (118)
- Induction of epithelial chloride secretion by channel-forming cryptdins 2 and 3. (1997) (116)
- Guanylin: a peptide regulator of epithelial transport 1 (1995) (114)
- Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. (1994) (114)
- Evidence for α-1 adrenergic receptor regulation of atriopeptin release from the isolated rat heart (1986) (110)
- Inhibition of Aldosterone Biosynthesis by Atriopeptins in Rat Adrenal Cells (1985) (106)
- Distribution of heat-stable enterotoxin/guanylin receptors in the intestinal tract of man and other mammals. (1994) (104)
- Potential role of nitric oxide in a model of chronic colitis in rhesus macaques. (1995) (101)
- Guanylin stimulation of Cl- secretion in human intestinal T84 cells via cyclic guanosine monophosphate. (1993) (97)
- Human guanylin: cDNA isolation, structure, and activity (1992) (88)
- Atriopeptins: renal-specific vasodilators in conscious dogs. (1985) (86)
- Natriuretic and kaliuretic activities of guanylin and uroguanylin in the isolated perfused rat kidney. (1998) (85)
- Comparative Vascular Pharmacology of the Atriopeptins (1985) (81)
- Uroguanylin: cloning of preprouroguanylin cDNA, mRNA expression in the intestine and heart and isolation of uroguanylin and prouroguanylin from plasma. (1996) (79)
- Rat guanylin cDNA: characterization of the precursor of an endogenous activator of intestinal guanylate cyclase. (1992) (78)
- Prouroguanylin and proguanylin: purification from colon, structure, and modulation of bioactivity by proteases. (1996) (76)
- Synthesis and biological characterization of L-N(6)-(1-iminoethyl)lysine 5-tetrazole-amide, a prodrug of a selective iNOS inhibitor. (2002) (74)
- 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. (1996) (71)
- Renal arachidonic acid metabolism. (1984) (67)
- Immunohistochemical localization of guanylin in the rat small intestine and colon. (1995) (66)
- The effect of inhibitors of inducible nitric oxide synthase on chronic colitis in the rhesus monkey. (1997) (63)
- Gastrointestinal pain: Unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation (2013) (63)
- Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. (2014) (61)
- Cyclic GMP down-regulates atrial natriuretic peptide receptors on cultured vascular endothelial cells. (1991) (59)
- Atriopeptin inhibition of thrombin-mediated changes in the morphology and permeability of endothelial monolayers. (1989) (56)
- Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial (2015) (56)
- Atriopeptin release from the isolated perfused rabbit heart. (1984) (54)
- Atrial natriuretic peptide inhibits oxidant-induced increases in endothelial permeability. (1991) (52)
- 2-Iminopyrrolidines as potent and selective inhibitors of human inducible nitric oxide synthase. (1998) (50)
- Atrial natriuretic peptide regulation of endothelial permeability is mediated by cGMP. (1990) (50)
- Kallikrein activation of a high molecular weight atrial peptide. (1984) (50)
- Substituted 2-iminopiperidines as inhibitors of human nitric oxide synthase isoforms. (1998) (47)
- Atriopeptins: correlation between renal vasodilation and natriuresis. (1985) (47)
- Reduction in the structural changes of experimental osteoarthritis by a nitric oxide inhibitor. (1999) (47)
- The soluble guanylate cyclase stimulator IW‐1973 prevents inflammation and fibrosis in experimental non‐alcoholic steatohepatitis (2018) (46)
- Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial (2017) (45)
- The sequence of an atriopeptigen: a precursor of the bioactive atrial peptides. (1984) (45)
- Atriopeptins: potential mediators of an endocrine relationship between heart and kidney (1984) (44)
- Atrial and brain natriuretic peptides share binding sites in the kidney and heart. (1989) (43)
- Distribution of Escherichia coli heat-stable enterotoxin/guanylin/uroguanylin receptors in the avian intestinal tract. (1995) (42)
- Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease (2018) (41)
- Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain (2014) (38)
- Opossum colonic mucosa contains uroguanylin and guanylin peptides. (1996) (37)
- Natriuretic and kaliuretic activities of guanylin and uroguanylin in the isolated perfused rat kidney. (1998) (36)
- Nitric oxide participates in the regulation of pancreatic acinar cell secretion. (1994) (35)
- Structure and activity of uroguanylin and guanylin from the intestine and urine of rats. (1997) (32)
- Guanylin mRNA is expressed in villous enterocytes of the rat small intestine and superficial epithelia of the rat colon. (1993) (32)
- Guanylyl cyclase receptors and guanylin-like peptides in reptilian intestine. (1997) (32)
- Inducible nitric oxide synthase and guinea-pig ileitis induced by adjuvant (1995) (32)
- Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions (2018) (31)
- Manganese potentiation of nitric oxide-mediated vascular relaxation. (1994) (31)
- 2-Iminohomopiperidinium salts as selective inhibitors of inducible nitric oxide synthase (iNOS). (1998) (31)
- sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH (2019) (30)
- Nitric oxide and the cyclooxygenase pathway. (1995) (30)
- Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans. (2016) (29)
- Inhibitors of human nitric oxide synthase isoforms with the carbamidine moiety as a common structural element. (1996) (28)
- The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials (2014) (28)
- Effects of Single Dose Administration of MD-1100 on Safety, Tolerability, Exposure, and Stool Consistency in Healthy Subjects: 894 (2005) (28)
- Synthesis and evaluation of two positron-labeled nitric oxide synthase inhibitors, S-[11C]methylisothiourea and S-(2-[18F]fluoroethyl)isothiourea, as potential positron emission tomography tracers. (1996) (27)
- Atriopeptin distribution in the developing rat heart (2004) (26)
- Proteolytic activation of a bioactive cardiac peptide by in vitro trypsin cleavage. (1984) (26)
- NITRIC OXIDE ACTIVATES THE CYCLOOXYGENASE PATHWAY IN INFLAMMATION (1995) (26)
- Atriopeptin stimulates chloride secretion in cultured shark rectal gland cells. (1991) (25)
- An evaluation of the FDA Responder Endpoint for IBS‐C clinical trials: analysis of data from linaclotide Phase 3 clinical trials (2013) (23)
- Acetamidine lysine derivative, N-(5(S)-amino-6,7-dihydroxyheptyl)ethanimidamide dihydrochloride: a highly selective inhibitor of human inducible nitric oxide synthase. (1998) (23)
- IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial. (2020) (23)
- Potentiation of Nitric Oxide-Mediated Vascular Relaxation by SC52608, a Superoxide Dismutase Mimic (1995) (22)
- Cell culture of renal epithelium derived from rabbit microdissected cortical collecting tubules. (1983) (21)
- Glucocorticoid regulation of atrial natriuretic peptide receptors on cultured endothelial cells. (1991) (21)
- Structure and activity of uroguanylin and guanylin from the intestine and urine of rats. (1997) (20)
- 286 Efficacy and Safety of Once Daily Linaclotide Administered Orally for 12-Weeks in Patients With Chronic Constipation: Results From 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials (2010) (20)
- MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux (2015) (18)
- A randomized controlled and long‐term linaclotide study of irritable bowel syndrome with constipation patients in Japan (2018) (18)
- The soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure. (2020) (18)
- Localization of exaggerated prostaglandin synthesis associated with renal damage. (1981) (18)
- High‐dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double‐blind, placebo‐controlled study with a long‐term open‐label extension study in Japan (2018) (18)
- Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C (2014) (17)
- Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease (2020) (16)
- An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension (2019) (15)
- Effects and interactions of parathyroid hormone and prostaglandins on adenosine 3',5'-monophosphate concentrations in isolated renal tubules. (1979) (14)
- A Randomized, Placebo‐Controlled, Multiple‐Ascending‐Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects (2018) (14)
- The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases (2021) (14)
- The Natriuretic Peptide Uroguanylin Elicits Physiologic Actions Through 2 Distinct Topoisomers (2009) (14)
- Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. (2020) (13)
- Co-localization of a kallikrein-like serine protease (arginine esterase A) and atrial natriuretic peptide in rat atrium. (1989) (13)
- Influence of calcium, parathyroid hormone and ionophore a-23187 on cyclic nucleotide concentrations of isolated renal tubules (1978) (13)
- Metabolism of cyclic AMP in isolated renal tubules: effects of prostaglandins and parathyroid hormone. (1979) (13)
- Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis (2019) (13)
- Tu1401 Factors Contributing to Treatment Satisfaction in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Treated With Linaclotide vs Placebo (2012) (12)
- Effect of glucocorticoids on the binding of atrial natriuretic peptide to endothelial cells. (1990) (12)
- Linaclotide Significantly Improved Bowel Habits and Relieved Abdominal Symptoms in Adults with Chronic Constipation: Data from a Large 4-Week, Randomized, Double-Blind, Placebo-Controlled Study (2008) (12)
- Induction of nitric oxide synthase regulates atrial natriuretic peptide receptors in vascular smooth muscle cells. (1993) (12)
- Regulation of atriopeptin release from the isolated rat heart (1986) (11)
- Profound elevation of ventricular and pulmonary atriopeptin in a model of heart failure. (1987) (11)
- The Mechanism and Site of the Enhanced Arachidonate Metabolism in Ureter Obstruction (1983) (11)
- Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C (2015) (11)
- ANTINOCICEPTIVE ACTIONS OF MD-1100, A NOVEL THERAPEUTIC AGENT FOR c-IBS, IN ANIMAL MODELS OF VISCERAL PAIN: 867 (2004) (10)
- Linaclotide Significantly Improved Abdominal Pain, Constipation and Global Assessments in Adults with Irritable Bowel Syndrome with Constipation: Results from a Large Twelve-Week, Randomized, Double-Blind, Placebo-Controlled Study (2008) (10)
- In vitro and in vivo evaluation of O-alkyl derivatives of tramadol. (2008) (10)
- A rapid and economical method of preparing radioiodinated cyclic nucleotide derivatives for use in radioimmunoassays. (1990) (10)
- Inhibition of Nitric Oxide Synthase and Prospects For Therapy in Inflammatory Diseases (1998) (10)
- Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications (2017) (10)
- Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications (2017) (10)
- Enhanced activity of the cardiac endocrine system during right ventricular hypertrophy (1989) (10)
- Dose‐finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double‐blind, and placebo‐controlled study (2018) (9)
- Difference in effect of atrial natriuretic peptide on cGMP in aortic and coronary smooth muscle cells. (1992) (8)
- Vasodilator properties of a family of bioactive atrial peptides in isolated perfused rat kidneys. (1985) (7)
- Temporal relationships of cytokine production in mouse non-lethal sepsis: Effect of nitric oxide synthase inhibitors (1997) (7)
- Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells. (2020) (7)
- Multiple-Ascending-Dose Study of the Soluble Guanylate Cyclase Stimulator, IW-1701, in Healthy Subjects (2017) (7)
- Targeted Delivery of Linaclotide to Specific Areas of The Intestine Affects Clinical Efficacy in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) (2017) (6)
- Inhibition of endothelial cell clearance of atrial natriuretic peptide by cyclic GMP treatment. (1992) (6)
- The Clinical-Stage sGC Stimulator IW-1701 Prevents Increase of Plasma Biomarkers of Intravascular Inflammation and Suppresses Leukocyte-Endothelial Interactions in Tnfα-Treated Mice (2017) (6)
- Characterization of the structure of preproguanylin. (1993) (6)
- Two Years on Linaclotide: Tolerability and Treatment Satisfaction in IBS-C Patients With and Without Diarrhea: Presidential Poster: 1791 (2014) (6)
- Suppression of atrial natriuretic peptide (ANP) receptor recovery from homologous down-regulation by 8-bromo-cGMP in endothelial cells. (1992) (6)
- T1817 Results From the Randomized Withdrawal Period of a Phase 3 Clinical Trial of Linaclotide in Chronic Constipation (2010) (5)
- Atriopeptins: bioactive peptides derived from mammalian cardiac atria. (1984) (5)
- The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system (2021) (5)
- Evidence for alpha-1 adrenergic receptor regulation of atriopeptin release from the isolated rat heart. (1986) (5)
- Fourteen-Day Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension (2018) (5)
- An impaired natriuretic peptide hormone system may play a role in COVID‐19 severity in vulnerable populations (2020) (5)
- Tu1068 Effects of Linaclotide Treatment on Patient-Reported Ratings of Change for Symptoms of Irritable Bowel Syndrome With Constipation (IBS-C): Pooled 12-Week Findings From Two Phase 3 Trials (2012) (4)
- Sa1098 Mediation Analysis Supports a Direct Effect of Linaclotide on Relief of Abdominal Pain Independent of Constipation Improvement (2012) (4)
- 236 Global Endpoints in IBS Clinical Trials: Results from a Phase 2B Study of Linaclotide (2009) (4)
- Tu1381 Effects of 26 Weeks of Linaclotide Treatment on Adequate Relief and IBS Severity in Patients With Irritable Bowel Syndrome With Constipation (2012) (4)
- Embryology of the endocrine heart (1989) (4)
- Praliciguat, a Clinical-Stage sGC Stimulator, Improved Glucose Tolerance and Insulin Sensitivity and Lowered Triglycerides in a Mouse Diet-Induced Obesity Model (2018) (4)
- Mo1856 Linaclotide Significantly Improved Abdominal Pain Compared With Placebo in Patients With Irritable Bowel Syndrome Regardless of Baseline Pain Severity in Two Phase 3 Trials (2012) (4)
- Th-P16:297 Early clinical characterization of MD-0727, a novel cholesterol absorption inhibitor, in healthy subjects (2006) (4)
- 875 - Iw-3718, a Novel Gastric-Retentive Bile Acid Sequestrant, Improved Heartburn and Regurgitation Symptoms in Patients with Persistent Gerd Despite PPI Treatment: A Double-Blind, Placebo-Controlled Study (2018) (4)
- FIRST-IN-HUMAN SINGLE-ASCENDING-DOSE STUDY OF IW-1973, A NEW SOLUBLE GUANYLATE CYCLASE STIMULATOR (2016) (4)
- Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical‐stage soluble guanylate cyclase stimulator in rats (2020) (3)
- Correlation between vascular and cellular responses to atrial natriuretic peptide and to sodium nitroprusside. (1994) (3)
- MRP 4 Modulation of the Guanylate Cyclase-C / cGMP Pathway : Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux s (2015) (3)
- The Effect of the Soluble Guanylyl Cyclase Stimulator Olinciguat on ƴ-Globin Gene Induction in K562 Cells (2018) (3)
- Evaluation of Daily GI Symptoms in a Phase 2A Study of IW‐9179 in Functional Dyspepsia: 2197 (2014) (2)
- Selective iNOS Inhibitors (2001) (2)
- Stimulation of soluble guanylate cyclase inhibited fibrosis and inflammation in human liver microtissues and in an animal model of liver disease (2018) (2)
- Mo2054 Assessing Abdominal and Bowel Symptoms Using Adequate Relief Based Thresholds: Results From 2 Phase 3 Trials of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (2013) (2)
- Atrial natriuretic peptide binding sites in the mammalian heart: Localization to endomural vessels (2004) (2)
- The Soluble Guanylate Cyclase Stimulator IW-1701 Enhances Nitric Oxide-Mediated Relaxation of Human Lower Esophageal Sphincter ex vivo (2017) (2)
- Temporal relationships of cytokine production in mouse non-lethal sepsis: effect of nitric oxide synthase inhibitors. (1997) (2)
- PWE-166 Is Response To Linaclotide After 4 Weeks Of Treatment Predictive Of 12-week Improvement? (2014) (2)
- Sa1094 Developing Benchmarks for Clinically Meaningful Change for IBS-C Symptoms Using Data From Two Phase 3 Trials of Linaclotide (2012) (2)
- Enhancement by ethanol of parathyroid-hormone-stimulated cyclic AMP accumulation in isolated renal tubules. (1983) (2)
- Tu1069 Do Baseline Factors Contribute to Treatment Satisfaction in Patients With Chronic Constipation Treated With Linaclotide vs Placebo (2012) (2)
- Evidence for Atrial Peptide Localization in Hematopoietic Cells (1986) (2)
- US immigration order strikes against biotech (2017) (2)
- Linaclotide is Effective and Safe for Patients with Irritable Bowel Syndrome with Constipation in Japan: A Phase III Randomized, Double-Blind, and Placebo-Controlled and Long-Term Extension Study (2017) (2)
- Interactions between parathyroid hormone and prostaglandins on renal cortical cyclic AMP. (1981) (2)
- Tu1211 IW-9179, a Phosphopeptide Designed to Target the Upper Gastrointestinal Tract, Is More Potent at Acidic pH and Is Rapidly Metabolized In Vitro in Rodent Intestinal Fluid (2015) (2)
- Rapid Dose Escalation Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension (2018) (2)
- 157 Effect of Linaclotide On IBS-C Symptoms in the First Week of Treatment: Results from a Phase 2B Study (2009) (2)
- Abstract P493: Multiple-ascending-dose Study of IW-1973, a Soluble Guanylate Cyclase Stimulator (2017) (2)
- IW-3718, a Novel Gastric-Retentive Bile Acid Sequestrant, Improved Symptoms of Refractory GERD in a Double-Blind, Placebo-Controlled Phase 2a Study: 1661 (2015) (2)
- PWE-167 Effect Of Linaclotide On Ibs-qol Sexual Subscale Scores In Patients With Irritable Bowel Syndrome With Constipation: Results From 2 Phase 3 Trials (2014) (1)
- T1273 Time to Onset of Linaclotide Effect On the Bowel Habits in Patients with Chronic Constipation: Results from a Phase 2B Study (2009) (1)
- Linaclotide induces secretion of cGMP from mouse colonic epithelium (2013) (1)
- Differential Bile Acid Detection in Refractory GERD Patient Saliva Using a Simple and Sensitive Liquid Chromatography Tandem Mass Spectrometry Approach (2021) (1)
- 956 IW-9179, a Potent Guanylate Cyclase-C (GC-C) Agonist, Improves Gastric Emptying In Vivo and Modulates Gastric Vagal Afferent Mechanosensitivity In Vitro (2015) (1)
- The soluble guanylate cyclase stimulator IWP‐550 inhibits neuroinflammation in vitro and in vivo (2018) (1)
- Effects of Linaclotide on Abdominal and Bowel Symptoms Over the First Seven Days of Treatment in Patients with Irritable Bowel Syndrome with Constipation: 1747 (2012) (1)
- Mo1858 Characterization and Association of Abdominal Pain With Anxiety or Depression in Patients With Irritable Bowel Syndrome With Constipation (2012) (1)
- Effects of prostacyclin and prostaglandin E1 on cyclic AMP metabolism and calcium efflux in isolated renal cortical tubules. (1980) (1)
- Pharmacology of the cardiac endocrine system (1989) (1)
- 1073-P: Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Diabetic Kidney Disease (2020) (1)
- Mo1515 - Bile Acid Sequestrant Shows Effects on the Contractile Activity of Ex Vivo Lower Esophageal Sphincter Muscle (2018) (1)
- 1924-P: Praliciguat, a Clinical-Stage sGC Stimulator, Improves Insulin Sensitivity, Lipid Tolerance, and Energy Utilization in a Mouse Diet-Induced Obesity Model Housed at Thermoneutrality (2019) (1)
- Su2033 Determining the Minimum Duration for Initial Treatment With Linaclotide in IBS-C Patients: Results From Pooled Phase 3 Trials (2013) (1)
- Sa2008 Efficacy and Safety of Linaclotide in Chronic Idiopathic Constipation Patients With Abdominal Bloating: Phase 3b Trial Results (2014) (1)
- 12 – Impact of Iw-3718, a Novel Gastric-Retentive Bile Acid Sequestrant, on a Spectrum of Gerd Symptoms in Patients with Persistent Gerd Receiving Ppis – Results from a Double-Blind, Placebo-Controlled Study (2019) (1)
- Week 1 Changes in Bowel and Abdominal Symptoms Following Linaclotide Treatment: Results from Two Phase 3 Trials in Chronic Constipation Patients: 1303 (2010) (1)
- A Comparison of the Physical and Pharmacological Properties of Plecanatide (SP-304) and the Human Hormone Uroguanylin: 1340 (2011) (1)
- Tu1423 Effects of Linaclotide on Straining Associated With Bowel Movements in Patients With Irritable Bowel Syndrome With Constipation (IBS-C): A Post Hoc Analysis of Pooled Data From Two Phase 3 Trials (2012) (1)
- Tu1380 Assessing the Percent of Days Linaclotide Improved Abdominal Symptoms and Stool Frequency in Patients With IBS-C: A Pooled Analysis of Two Phase 3 Trials (2012) (1)
- 418 Effect of Linaclotide On Quality of Life in Adults with Chronic Constipation: Results from a Phase 2B Study (2009) (1)
- 848 Efficacy of Linaclotide in Improving Abdominal Symptoms Rated as Most Severe by Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (2012) (1)
- Correlation of Global Assessments with Symptom Endpoints in Phase 3 Clinical Trials of Linaclotide in Chronic Constipation: 1304 (2010) (1)
- Linaclotide Treatment Results in Significant Improvements in Abdominal and Bowel Symptoms in IBS-C Patients with Severe Abdominal Pain at Baseline: 1341 (2010) (1)
- Conference Date Presenter Title/Topic (2003) (0)
- Use of sgc stimulators for the treatment of esophageal motility disorders (2017) (0)
- Dose-Finding of Linaclotide for Patients with Chronic Constipation in Japan: A Phase II Randomized, Double-Blind, and Placebo-Controlled Study (2017) (0)
- Methods and compositions for the treatment of gastrointestinal diseases (2004) (0)
- ATRIOPEPTINS: NATRIURESIS OCCURS INDEPENDENT OF VASCULAR EFFECTS (1984) (0)
- Adenocarcinoma Cells via Cyclic GMP Mouse and Induces Apoptosis in Human Colon Min / + Apc Uroguanylin Treatment Suppresses Polyp Formation in the Updated (2000) (0)
- PWE-027 Mediation Analysis Supports a Direct Effect of Linaclotide (LIN) on Abdominal Pain (AP) Relief Independent of Constipation Improvement (2013) (0)
- Amidino derivatives as no-synthetase inhibitors (1994) (0)
- Response to Miner et al. (2017) (0)
- Effects of Linaclotide on Bowel Movements (BMs) and Straining in Patients with Chronic Constipation (CC): A Post Hoc Analysis of Pooled Data from Two Phase Three Trials: 1745 (2012) (0)
- Radioimmunoassay of Atrial Peptide Blood and Tissue Levels (1987) (0)
- Reciprocal effects of mucosal PH on cgmp and CI secretion responses of intestinal cells to uroguanylin and guanylin (1996) (0)
- COMPOSITIONS AND METHODS FOR TREATING NONALCOHOLC FATTY LIVER DISEASE-ASSOCATED DSORDERS Inventor: (2017) (0)
- 1081-P: Metabolic Effects of Praliciguat, Empagliflozin, and Their Combination in Rats with Programmed Hypertension and Early Exposure to High-Fat Diet (2020) (0)
- Nitrite and nitrate derivatives are useful as anti-inflammatory steroid drugs. (1997) (0)
- Compositions for the treatment of gastro-intestinal disorders (2004) (0)
- I D IS O R D E R S A 12-Week , Randomized , Controlled Trial With a 4-Week Randomized Withdrawal (2012) (0)
- Derivatives containing the amidino group, useful as inhibitors of nitric oxide synthase. (1994) (0)
- TREATMENT OF GASTRONTESTINAL DSORDERS (2017) (0)
- PWE-029 Characterisation and Association of Abdominal Pain With Anxiety or Depression in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) (2013) (0)
- A Comparison of Different Primary Endpoints Used to Evaluate Treatments for Irritable Bowel Syndrome with Constipation: Results from a Phase 2b Study of Linaclotide: 1327 (2011) (0)
- Esters novel nitrite / nitrate drugs useful as antiinflammatory drugs. (1996) (0)
- 1587 ATRIOPEPTIN: A POWERFUL NATRIURETIC IN RATS WITH RENAL FAILURE (1985) (0)
- Acetamidine Lysine Derivative, N‐(5(S)‐Amino‐6,7‐dihydroxyheptyl)ethanimidamide Dihydrochloride: A Highly Selective Inhibitor of Human Inducible Nitric Oxide Synthase. (1998) (0)
- Methodes et compositions pour le traitement de troubles gastro-intestinaux (2004) (0)
- EFFECTS OF PARATHYROID HORMONE ON CYCLIC NUCLEOTIDE LEVELS AND EFFLUX OF CALCIUM IN ISOLATED RENAL CORTICAL TUBULES (1981) (0)
- Effects of a Gastric-Retentive Extended-Release Bile Acid Sequestrant on Esophageal Erosions in Patients With Persistent GERD: Exploratory Analysis From a Phase 2B Study of IW-3718 (2018) (0)
- Compositions for treating gastrointestinal sicknesses (2004) (0)
- Su1089 - Presence of Bile Acids Detected in Human Saliva using a Novel Sensitive Bioanalytical Method: A Comparative Study in Patients with Persistent or Controlled Gerd Symptoms and Healthy Subjects (2018) (0)
- PWE-026 Effects of 26 Weeks of Linaclotide Treatment on Adequate Relief and IBS Severity in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) (2013) (0)
- Tu1065 Comparison of Responder Rates and Degree of Agreement for Symptom-Specific and Global-Relief Endpoints in Two Phase 3 Trials of Linaclotide in IBS-C (2012) (0)
- Efficacy and Safety of Once-daily Linaclotide Administered Orally for 12-Weeks in Patients with Chronic Constipation: Pooled Results from 2 Randomized, Double-blind, Placebo-controlled Phase 3 Trials: 1339 (2010) (0)
- Composes indole utiles (2006) (0)
- Abstract 16938: IW-1973 is a Potent Soluble Guanylate Cyclase Stimulator in vitro and in vivo With Extensive Tissue Distribution (2016) (0)
- Expression of cyclooxygenase and regulation by interleukin-1β in human osteoarthritis tissues (1999) (0)
- Linaclotide Significantly Improves Post-Operative Ileus and Opiate-Induced Constipation in Rats: 1257 (2006) (0)
- Polypeptide and pharmaceutical composition and the use thereof. (2006) (0)
- Procedures and compositions for the treatment of gastrointestinal disorders (2004) (0)
- 124-LB: Praliciguat, a Clinical-Stage Soluble Guanylate Cyclase (sGC) Stimulator, Improved Oral Glucose and Lipid Handling and Slowed Diabetic Weight Loss in TALLYHO Mice (2020) (0)
- Report from the Scientific Poster Session at the 12th Annual Cardiometabolic Health Congress in Boston, USA, 4–7 October 2017 (2017) (0)
- Linaclotide Efficacy on Dyspepsia Symptoms Using Nepean Dyspepsia Index (NDI) in a Phase 3B Trial of CIC Patients With Bloating: 1818 (2014) (0)
- PWE-028 Significantly Improved Abdominal Pain (AP) with Linaclotide (LIN) vs Placebo (PBO) in Patients (PTS) with Irritable Bowel Syndrome (IBS) Regardless of Baseline Pain Severity in 2 Phase 3 Trials (2013) (0)
- Composition for the treatment of gastrointestinal disorders (2004) (0)
- The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system (2021) (0)
- Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications (2017) (0)
- Activation of the guanylate cyclase-C/cGMP pathway decreases gastrointestinal pain (2013) (0)
- Modulateurs de crth2, de cox-2 et de faah (2005) (0)
- Inhibition of Fatty Acid Amide Hydrolase (FAAH) Reduces Contextually Elicited Gaping, a Measure of Anticipatory Nausea in Rats: 132 (2014) (0)
- PWE-025 Assessing the Percent of Days Linaclotide Improved Abdominal Symptoms and Stool Frequency in Patients with Irritable Bowel Syndrome with Constipation (IBS-C): Pooled Analysis of 2 Phase 3 Trials (2013) (0)
- SUN-662 Praliciguat, a Clinical-Stage Soluble Guanylate Cyclase Stimulator, Improves Lipid Handling and Insulin Sensitivity in Diet-Induced Obese Mice (2020) (0)
- Tu1070 The Effect of Linaclotide on IBS-QOL Sexual Subscale Scores in Patients With Irritable Bowel Syndrome With Constipation: Results From a Post Hoc Analysis of 2 Phase 3 Trials of Linaclotide (2013) (0)
- New derivatives ester nitrite / nitrate steroids useful as anti-inflammatory drugs (1996) (0)
- Tu1627 - Linaclotide is Effective and Safe for Patients with Chronic Constipation in Japan: A Phase III Randomized, Double-Blind, Placebo-Controlled Study with a Long-Term Open-Label Extension Study (2018) (0)
- Compositions et methodes de traitement de troubles gastro-intestinaux (2006) (0)
- Quantitative mass balance, tissue distribution, pharmacokinetics and biotransformation pathway of praliciguat, a clinical-stage sgc stimulator, after oral administration in rats (2019) (0)
- Sa1421 The Effect of Comorbid Psychological Distress on Baseline Irritable Bowel Syndrome With Constipation Symptoms and Response to Linaclotide Treatment (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Mark. G. Currie?
Mark. G. Currie is affiliated with the following schools:
